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Summary
At high altitude, reduced atmospheric pressure
causes the partial pressure of oxygen to decrease –
creating an environment of hypobaric hypoxia
which presents a unique set of challenges for the
respiratory system. Pulmonary physiological re-
sponses such as the hypoxic ventilatory drive are
essential for successful acclimatisation, whilst oth-
ers such as hypoxic pulmonary vasoconstriction
may be implicated in the development of altitude ill-
nesses. Pulmonary conditions are some of the most
common (e.g. high altitude cough) and also the
most serious illnesses seen at altitude (e.g high al-
titude pulmonary oedema, HAPE). Minimising the
chance of developing HAPE through planning an
appropriate ascent profile should be strongly en-
couraged as HAPE can rapidly be fatal if left untreat-
ed. Whilst pharmacological agents such as nifedip-
ine can help with the management of HAPE, rapid
descent remains the single-most important treat-
ment option once symptomatic. Given the increas-
ing popularity of travelling to altitude, an awareness
of how hypobaric hypoxia affects chronic respirato-
ry conditions such as asthma and chronic obstruc-
tive pulmonary disease (COPD) is also becoming in-
creasingly important for respiratory physicians.
KEY WORS: altitude, hypoxia, hypoxic, pulmonary
oedema, acclimatisation, adaptation, cough, asthma,
COPD, chronic obstructive pulmonary disease, hypo-
baric.
Introduction
High altitude presents a unique set of challenges for the
respiratory system.  With increasing altitude the air be-
comes colder and dryer and as barometric pressure
falls, so too does the atmospheric partial pressure of
oxygen (PATO2). At 5300m (the height of Everest base
camp) there is only half of the amount of oxygen avail-
able for inspiration compared to sea level due to the low-
er atmospheric pressure (1, 2). 
This hypobaric hypoxia causes a number of problems
for over 100 million people who live, work or visit altitude
environments every year (3). Physiological changes are
detectable as low as 1500m and altitude related illness
is increasingly common at high altitude (defined as alti-
tudes greater than 2500m) (4-6). Pulmonary conditions
(e.g. lower respiratory tract infections and cough) are
the most common medical conditions seen in altitude
clinics, making a good understanding of respiratory
pathophysiology at high altitude essential (7).
Aims of this review
The aims of this review are to explain the respiratory
components of successful acclimatisation to altitude;
describe the pathophysiology, prevention and manage-
ment of common altitude-related respiratory illnesses
such as high altitude pulmonary oedema (HAPE) and
high altitude cough; and finally to offer an understanding
of how hypobaric hypoxia affects chronic respiratory
conditions such as asthma and chronic obstructive pul-
monary disease (COPD). Searches were conducted on
Medline and Web of Science databases using terms ‘al-
titude’ and ‘pulmonary oedema’ or ‘cough’ or ‘respirato-
ry illness’ or ‘asthma’ or ‘COPD’. Relevant articles were
then selected (with particular focus given to articles pub-
lished within the last 5 years) and the reference lists of
identified articles were scrutinised.
Acclimatisation
The process of physiological adaptation to a high alti-
tude environment is called acclimatisation and whilst
some changes occur within minutes, others take days or
weeks to be fully expressed (1, 4). Classical teaching
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emphasises the importance
of increased oxygen delivery
to the peripheral tissues in
this process, and indeed
respiratory rate, heart rate,
cardiac output and red cell
mass do all increase as part
of an early acclimatisation
response (4, 8). However it
is becoming increasingly
clear that changes occur at
every stage of the oxygen transport cascade with tissue-
level changes to the microcirculation and mitochondria
being important (9, 10). Genetic (especially the HIF1α
pathway) and epigenetic mechanisms are now recog-
nised as being responsible for these physiological adap-
tations (11, 12). It has also become apparent that
changes in oxygen utilisation may be at least as impor-
tant as augmentation of oxygen delivery in the develop-
ment of successful acclimatisation. Two physiological
respiratory responses to hypoxia merit detailed discus-
sion – the hypoxic ventilatory response and hypoxic pul-
monary vasoconstriction.
Hypoxic ventilatory response
The hypoxic ventilatory response (HVR), believed to be
one of the most important elements of acclimatisation, is
the increase in ventilation trig-
gered by exposure to acute
hypoxia. This response is
non-linear with distinct
phases. The initial increase
in ventilation is classically
explained by peripheral
chemoreceptor stimulation.
A decrease in the arterial
partial pressure of oxygen
(PaO2) is detected in the
glomus cells of the carotid
bodies, resulting in increased stimulation of the central
respiratory centres in the medulla and causing an in-
crease in respiration rate (RR), ventilation and PaO2.
However, this increased ventilation also leads to a de-
crease in the arterial partial pressure of CO2 (PaCO2).
This reduces the overall respiratory drive, causing this
initial hypoxia driven response to be blunted and allows
PaCO2 to tend back towards normality again over the
next 20 to 30 minutes. 
Respiratory acclimatisation occurs more gradually as
both the HVR and the hypercapnic respiratory ventilato-
ry response (HCVR) continue to increase over the fol-
lowing days to weeks although the exact mechanism
behind these changes remains unclear. Metabolic com-
pensation through renal bicarbonate loss may play a
part but the time-course of this process does not match
observed changes in ventilation (8, 13). An interesting
hypothesis explaining why the HVR response has dis-
tinct acute and gradual phases relates to cerebral blood
flow autoregulation, a well-recognised homeostatic phe-
nomenon that conserves cerebral oxygen delivery (DO2)
by increasing blood flow in response to hypoxaemia.
Whilst cerebral hypoxaemia is more normally due to in-
creased metabolic activity resulting in higher cellular
oxygen utilisation, Wolff notes that this autoregulatory
response also serves to preserve DO2 when hypox-
aemia is due to hypobaric hypoxia (i.e. at altitude) (14).
He notes that maintenance of cerebral oxygenation dur-
ing hypoxaemia occurs through hypoxic cerebral va-
sodilation resulting in elevated cerebral blood flows, but
that this in turn will result in ‘washout’ of CO2. The result-
ing hypocapnia should tend to cause cerebral vessels to
vasoconstrict and thereby blunt this initial response, but
Wolff suggests that the hypoxic vasodilation response
seems to outweigh this effect as overall flows increase,
peaking at 8hrs after hypoxic exposure in his studies
(14, 15). Local hypocapnia driven by increased cerebral
blood flow results over time in reduced levels of bicar-
bonate ions as a buffering response with a new ‘set-
point’ being one candidate mechanism underpinning the
HCVR (14). Wolff’s hypothesis could neatly explain the
different time-courses of phasic responses to hypoxia
and also suggests that HVR is controlled centrally as
opposed to peripherally with the main stimulus being to
maintain cerebral oxygen delivery.
Hypoxic pulmonary vasoconstriction
As well as changes in HVR, decreases in PaO2 also
cause the pulmonary vascular bed to rapidly constrict.
Together with the increases in cardiac output described
above, this hypoxic pulmonary vasoconstriction (HPV)
results in increased pulmonary arterial pressures (8).
Like HVR, HPV occurs within minutes of hypoxic expo-
sure (16). It is thought to be mediated through oxygen
sensitive voltage gated
potassium channels in the
pulmonary vasculature re-
sulting in smooth muscle
constriction – a widely con-
served and beneficial re-
sponse believed to have
evolved to optimise ventila-
tion perfusion matching by
reducing blood flow to rela-
tively hypoxic alveoli (17). One
important benefit of this is to facilitate the transition from
fetal to neonatal circulation at the time of birth. When the
fetal lungs are unventilated in utero and PaO2 is ex-
tremely low, HPV completely occludes pulmonary flow
and diverts blood through the duetus arterioles into the
fetal systemic circulation. However after the neonate’s
first breath this pulmonary hypoxaemia is rapidly re-
versed, pulmonary vasoconstriction decreases and the
pulmonary circulation starts to open with flow being
closely matched to the alveoli which are recruited first (to
minimise shunting) until ultimately all of the alveoli are
both ventilated and receiving pulmonary blood flow (17).
However HPV may also have harmful consequences
when global hypoxaemia results in widespread vaso-
constriction. A brisk HPV is likely central to the patho-
genesis of high altitude pulmonary oedema (HAPE),
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whilst having a normal or low HPV response seems pro-
tective against the condition (18, 19). 
Interestingly, Tibetans – who are supremely adapted to
living at altitude – have a larger hypoxic ventilatory re-
sponse and a much smaller hypoxic pulmonary vaso-
constrictive response than native lowlanders. This is
possibly due to high levels of nitric oxide, a potent va-
sodilator which Tibetans exhale in much larger volumes
than Western lowlanders (20). 
High altitude pulmonary oedema (HAPE)
HAPE, first described in 1960, is a non-cardiogenic pul-
monary oedema associated with heterogeneously ele-
vated pulmonary artery pressure and consequent pul-
monary capillary stress failure. This in turn causes leak-
age of protein and cell-rich fluid into the alveolar spaces
impairing gas exchange. It typically occurs within 2-5
days of ascending to altitude (8, 21-23). Whilst classical-
ly occurring above 2500m it
has also been described at
altitudes as low as 1400m
(24). Quoted incidences de-
pend on speed and magni-
tude of ascent but vary be-
tween 0.2% if 4500m is
reached in 4 days up to 15%
if 5500m is reached within 2
days (25). It is the most com-
mon cause of medical evac-
uation from Everest base
camp (7) and one of the two most serious altitude relat-
ed illnesses with an estimated mortality rate reportedly
as high as 50% if not treated (5, 25). Native highlanders
(including Tibetans/Sherpas) and experienced guides
have also been described with the condition in the liter-
ature (26, 27).
HAPE can occur with or
without preceding symptoms
of acute mountain sickness
(AMS) and whilst in severe
cases patients can be fever-
ish (up to 38.5°C), dyspnoeic,
tachycardic, hypoxic and often coughing pink and frothy
sputum; symptoms of mild disease may be as subtle as
decreased performance with a dry cough. Consequent-
ly a high degree of suspicion is essential to aid early de-
tection (4, 5, 8). 
Risk factors
Certain population groups have been suspected of hav-
ing a genetic predisposition to developing HAPE (28). A
recent review identified a number of possible gene muta-
tions that may be linked to the pathogenesis and devel-
opment of HAPE – many are downstream targets of HIF-
1α and also involved in either HPV or HVR. These include
the angiotensin-1 converting enzyme (ACE), vascular
endothelial growth factor (VEGF), tyrosine hydroxylase
(TH), serotonin transporter (5HTT), endothelin 1 (EDN1)
and endothelial nitric oxide synthase (eNOS) genes (29).
HAPE has also recently been associated with an overac-
tive sympathetic nervous system, (30) the major-histo-
compatibility complex, (31) an increase in hepcidin levels
(32) as well as lack of oestrogen (33). 
What is certain though is that HAPE incidence increas-
es at higher altitudes and particularly with more rapid
rates of ascent – indeed rate of ascent has the strongest
association with disease incidence (34). Young age and
male gender are also both widely accepted risk factors
and there is now growing evidence to suggest that an in-
ter-current illness, particularly with a viral lower respira-
tory tract infection, also increases the risk of developing
HAPE (35, 36). 
Prevention
There has recently been significant interest amongst
high altitude visitors in using low-level hypoxic cham-
bers (most of which tend to generate a normobaric hy-
poxic environment through reducing the fractional oxy-
gen concentration rather than altering barometric pres-
sure) as a form of pre-acclimatisation to allow for a more
rapid ascent profile later. This remains a very controver-
sial area which is still being actively debated (37). How-
ever, recent data synthesis from a 2013 review evaluat-
ing the effectiveness of pre-acclimatisation strategies in
acute mountain sickness, and a more recent systematic
review comparing the physiological effects of normobar-
ic and hypobaric hypoxia, suggest that normobaric hy-
poxia is not as effective at inducing acclimatisation as
hypobaric hypoxic exposure and these two environ-
ments are not physiologically equivalent (38, 39). 
Currently international guidelines from the Wilderness
Medical Society do not support pre-acclimatisation, but
rather recommend a slower ascent/longer acclimatisa-
tion as the best way to minimise the risk of developing
altitude illnesses, including HAPE (40). Therefore plan-
ning appropriate itineraries should be actively encour-
aged and current recommendations suggest ascending
no more than 500m sleeping altitude each day once
above 3000m and including a rest day for every 3 to 4
days of ascent (40).
Pharmacological prevention and management of HAPE
has focussed on reducing HPV. Nifedipine modified re-
lease 30mg twice a day is recommended as first line
preventative therapy (41). Other agents such as tadalafil
(10mg twice a day), dexamethasone (8mg twice a day)
and salmeterol (in very high doses of 125μg twice a day,
which may cause side effects) have all been shown to
be effective in preventing HAPE in susceptible individu-
als in randomised control trials (42, 43). However, these
trials were relatively small (29 and 37 subjects respec-
tively) and clinical experience with these agents is limit-
ed. Consequently, these other agents are currently only
recommended to be used as adjunctive therapies to
nifedipine (40). 
Theoretically acetazolamide (which encourages earlier
bicarbonate diuresis through inhibiting renal carbonic
anhydrase) should also prevent HAPE in the same way
that it prevents other altitude illness (by accelerating ac-
climatisation), but this has not yet been realised in clini-
cal trials (40, 44). Interestingly Acetazolamide has been
shown to reduce HPV in dogs independently of its ef-
fects on carbonic anhydrase (45-47). 
A. Cumpstey et al.
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Management
Descent remains the single most important treatment for
anyone suspected of having HAPE (immediate increase
in PiO2). Patients should aim to descend a minimum of
300-1000m, or until symptoms have fully resolved, with
minimal exertion (e.g. ideally by mechanised or animal
transport) as exertion can elevate pulmonary pressures
and further worsen oedema (4, 5, 40).
‘Artificial descent’ can be initiated temporarily by using a
Portable Altitude Chamber (PAC) or ‘Gamow’ bag and
this has been used successfully in cases of HAPE (48).
However this should only be considered when actual
descent is logistically impossible (e.g. due to inclement
weather), as keeping the chamber pressurised is labour
intensive, there are risks of baro-trauma to the ears and
the patient is obliged to return to the pressure of the out-
side altitude/environmental pressure as soon as they
leave the chamber. Furthermore, for very sick patients,
access for medical interventions is delayed and this may
result in harm (for example in the case of sudden loss of
consciousness).
Supplemental oxygen should be given to patients if it is
available, although this is often not possible outside of
specialist altitude clinics. The 1st pharmacological treat-
ment is again nifedipine MR 30mg BD based on one
randomised control trial and lots of international clinical
experience (49). There is no good evidence to prove the
effectiveness of using b-agonists (e.g. salmeterol),
steroids (e.g. dexamethasone) or phosphodiesterase in-
hibitors (e.g. tadalafil) in the treatment of HAPE (40).
However, in practice many HAPE patients are treated
with many of these agents as adjuncts to nifedipine and
most importantly descent where possible (26).
High altitude cough
High altitude cough is one of the most common present-
ing complaints in altitude clinics (7). It can result in seri-
ous consequences, such as fractured ribs, yet it remains
very poorly understood and treatments remain remark-
ably limited (50, 51). This is at least in part due to a lack
of research into the condition – the first study into high
altitude cough was only published in 1994, more than 30
years after the first published description of HAPE (52).
The aetiology of high altitude cough remains unclear.
Initially the cough was thought
to be due to altitude environ-
ments being cold and dry.
However this was ques-
tioned when almost every
subject in the Operation
Everest II study developed
worsening cough symptoms
as the simulated altitude in the
chamber increased beyond 7000m, despite the temper-
ature and humidity both remaining tightly controlled (53).
In a follow up chamber study, Operation Everest III, noc-
turnal cough frequency increased significantly in all 8
subjects at 5000m compared to sea level and the citric
acid cough threshold was significantly reduced at
8000m (but interestingly not at 5000m), again despite
High altitude respiratory physiology and pathophysiology
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tight control of chamber temperature and humidity (52).
Changes in bradykinin levels and changes to the hyper-
capnic ventilatory response have both been proposed
as possible aetiologies, but neither has shown positive
correlations with altitude cough in studies (54, 55).
Another possibility is that altitude cough may simply be
an early sign of subclinical acute mountain sickness
(AMS) or even HAPE. However Mason argues strongly
against this in his thorough review of altitude related
cough, noting how it has rarely been observed as a ma-
jor symptom in either clinical condition in multiple stud-
ies. Furthermore no association between cough and
AMS or HAPE has ever been scientifically demonstrat-
ed (51).
The relationship between other causes of cough at sea
level, such as inter-current viral illness or gastro-oe-
sophageal reflux, and high-altitude cough have yet to be
described at altitude (51). However neither of these
mechanisms would easily explain the clear correlation
between increasing altitude and worsening cough
severity.
In summary, cough is common and debilitating at alti-
tude. However its aetiology remains elusive and conse-
quently no specific management advice can be given
beyond trialling the many common treatments for symp-
tomatic relief from chronic cough at sea level.
Pre-existing lung disease at altitude
Asthma
Living at high altitude for long periods seems to reduce
the risk of developing asthma exacerbations. A study in
Mexico has demonstrated an inverse relationship be-
tween asthma prevalence and altitude of residence in
adults, and another study in Greece showed that the in-
cidence of asthma halved in children living at 800-
1200m compared to sea level residents (56, 57). This
may be due to reduced allergen exposure (e.g. to the
house dust mite) at altitude, or possibly also due to the
hypoxia driven increase in sympathetic tone, cortisol
and catecholamine activity resulting in reduced bron-
chospasm and airway obstruction through increased b2
receptor stimulation (58, 59).
However many of these studies are in long term altitude
residents and there are still theoretical risks to the low-
land asthma sufferers visiting altitude for short periods.
Hypobaric hypoxia at altitude makes anyone feel breath-
less and this will be no different in asthma sufferers. As
explained above, the increased ventilatory response to
this stimulus will consequently also lower levels of car-
bon dioxide resulting in increased airway resistance
(60). Breathing in cold dry air has also been shown to in-
crease peripheral airway resistance proportionally more
in asthmatic patients than in non-asthmatic controls
(61). And finally, metered dose inhalers may also work
less well at altitude due to the cold – emitting less of the
drug and with increased particle size.
Different field studies have now independently shown
that lowlanders with mild asthma can travel safely to the
summit of Kilimanjaro (5895m) and also to heights up to
6410m in the Everest region of the Himalayas given ad-
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equate preparation and support (59, 62). Sensible pre-
cautions would be carrying extra supplies of inhaler
medications and prednisolone to use in the event of
symptoms worsening or an exacerbation developing,
keeping inhalers as warm as possible and using a ban-
dana/buff or something similar over the mouth might al-
so help warm and humidify inspired air (60).
Chronic Obstructive Pulmonary Disease (COPD)
In contrast to asthma, it is widely acknowledged that liv-
ing at altitude has harmful effects on COPD patients.
Along with smoking, male gender and history of tubercu-
losis infection, living at altitude has been identified as an
independent risk factor for developing COPD across
Colombia and more recently in Peru, although both
studies only looked at urban (large city) environments
up to 2650m (63, 64). Furthermore, whilst living at alti-
tudes above 1500m in the US was generally associated
with an increase in life expectancy compared to sea lev-
el, increased altitude had a harmful and dose-related ef-
fect in COPD patients who also had a significantly high-
er mortality at altitude (3-4 more per 10,000 compared
to sea level) (65).
Altitude worsens both arterial hypoxaemia and pul-
monary vasoconstriction in COPD patients. Although
limited field studies have
been performed, one study
in 1978 showed that resting
PaO2 dropped to just
51.2mmHg within 3hrs of ar-
riving at 1920m altitude, and
PaO2 universally dropped
below 6.7 during light exercise
in a more recent chamber study with a simulated altitude
of 2438m (66, 67). Mean pulmonary artery pressure was
significantly higher in COPD patients resident at an alti-
tude of 1768m compared to sea level (36.05mmHg vs
26.78mmHg, p<0.001) (68). 
Importantly, treatment of other altitude illness may also
compound underlying COPD. Acetazolamide is one of
the most commonly used pharmacological agents for
both prevention and treatment of altitude related illness
as explained above. However, through its direct inhibi-
tion of carbonic anhydrase it both increases ventilation
and also inhibits carbon dioxide excretion, potentially re-
sulting in worsening respiratory failure in patients with
COPD. Consequently Luks and Swenson advise that if
acetazolamide is to be used at all in these patients it
should be used cautiously and the dose should be limit-
ed to just 125mg BD (69).
The British Thoracic Society guidelines on preparation
of patients for air travel are a useful starting point for ad-
vice on how best to prepare patients for visiting altitude
(airplane cabins often simulate altitudes of between
1500-2000m) (70). Patients with COPD who are consid-
ering high altitude travel should also consider carrying
extra rescue medications (prednisolone and/or antibi-
otics) as well as spare inhalers; consider how remote
their proposed destination is and ensure that their med-
ical insurance will cover full evacuation and repatriation
in the event of their condition worsening.
Conclusion
Hypobaric hypoxia can cause a number of pathophysio-
logical respiratory problems, including some of the most
common (e.g. cough) and the most serious (e.g. high al-
titude pulmonary oedema) altitude related ailments.  Hy-
poxia at altitude can also have significant effects on
chronic respiratory conditions such as chronic obstruc-
tive pulmonary disease. Further research is required to
improve understanding of these conditions and refine
treatments. Visitors to altitude should prepare carefully
(e.g. planning appropriate ascents and ensuring ade-
quate control of other conditions) before journeying to
altitude to minimise risks as much as possible.
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